Indefinite Delivery Contract 75D30121D10196
Award Date
12/31/20
Last Date to Order
2/28/22
Federal Agency
CDC Pittsburgh
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Centers for Disease Control and Prevention awarded an indefinite delivery contract to Glaxosmithkline, LLC for adult influenza vaccines. The contract has a potential value of $13.41 million to supply a minimum of 100 doses and maximum of 20 million doses of inactivated influenza vaccine for individuals aged 19 years and older through February 28, 2023. Vaccines must be licensed by the FDA and manufactured in compliance with cGMP regulations. Delivery locations include CDC distribution...
The Indefinite Delivery Contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh provides adult flu vaccines for the 2023-2024 period. Glaxosmithkline, LLC was awarded a multiple award contract with a potential value of $13.9 million to deliver flu vaccines through February 2028 under associated task orders or price lists. The solicitation aimed to procure adult flu vaccines to support the Centers for Disease Control and Prevention's...
The Centers for Disease Control and Prevention (CDC) awarded a single award Indefinite Delivery Contract to Glaxosmithkline, LLC, a pharmaceutical company, to procure pediatric influenza vaccines for the 2022-2023 season. The contract has a potential value of $168,590,000 and a period of performance from the date of award through February 28, 2023. The original solicitation sought between 100 doses and 50 million doses of pediatric influenza vaccine to be delivered to CDC distribution centers in...
This indefinite-delivery, indefinite-quantity (IDIQ) contract was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, to Glaxosmithkline, LLC, a pharmaceutical company, for the purchase of 12 standard adult vaccines. The $172.4 million contract has a one-year period of performance from July 1, 2022 to June 30, 2023 and does not utilize any set-asides. The vaccines, which include influenza, hepatitis, pneumococcal, and...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide adult influenza vaccines for the 2024-2025 season. The $13,916,000 multiple award IDC has a period of performance through February 28, 2025. The contract does not have any set-aside designations. Glaxosmithkline will likely provide the vaccines from its facilities in North Carolina to support the CDC's immunization programs...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a multiple award indefinite delivery contract to Seqirus USA Inc. for adult flu vaccines for 2023-2024. The potential value of the contract is $146,103,060. Orders may be placed through February 28, 2024. The contract aims to procure adult flu vaccines to support the CDC's efforts in disease prevention. As the leading public health agency in the United States, the CDC works to control and prevent...
The federal contract IDV award is a $13,916,000 Indefinite Delivery Contract issued by the Centers for Disease Control and Prevention (CDC) to GlaxoSmithKline, LLC to provide adult influenza vaccines for the 2025-2026 season. The contract has a period of performance through February 28, 2026. GlaxoSmithKline, a pharmaceutical company that supplies vaccines and other products to federal agencies, will deliver the seasonal flu vaccines under this multiple award IDV contract. The contract vehicle...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services, a civilian federal agency, to GlaxoSmithKline Holdings (Americas) Inc. The single-award contract has a ceiling value of $11,968,367.50 and a period of performance from March 15, 2010 to February 28, 2011. The contract aims to procure influenza vaccine services for the CDC's Vaccine for Children (VFC) program in 2010. The VFC program provides vaccines at no cost to...
The Centers for Disease Control and Prevention awarded Sanofi Pasteur Inc. a multiple-award indefinite delivery contract with a potential value of $67,076,901.90 to procure adult flu vaccines for 2023-2024. No set-aside was used for this award. Under the terms of the contract, the awardee will deliver flu vaccines to the CDC through the period ending February 28, 2024. The solicitation sought to procure adult flu vaccines in support of the CDC's efforts to prevent the spread of influenza. As the...
This single-award Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Sanofi Pasteur Inc. to provide adult influenza vaccines for the 2022-2023 flu season. The contract has a ceiling value of $65,825,903.80 and a period of performance from the date of award on December 31, 2021 through February 28, 2023. The original solicitation sought proposals for IDIQ contracts to supply a minimum of 100 doses and a maximum of 20 million doses of...